Epigenetic and genetic alterations in duodenal carcinomas are distinct from biliary and ampullary carcinomas

Gastroenterology. 2003 May;124(5):1300-10. doi: 10.1016/s0016-5085(03)00278-6.

Abstract

Background & aims: Carcinomas of the extrahepatic bile ducts, ampulla of Vater, and duodenum are uncommon, and their epigenetic and genetic alterations are not well characterized.

Methods: We therefore compared the methylation profile and genetic alterations in 18 extrahepatic biliary, 9 ampullary, and 12 duodenal carcinomas. We evaluated methylation at p16, p14, and human Mut L homologue (hMLH1) by methylation- specific PCR (MSP), and at cyclooxygenase 2 (COX2), O(6)-methyl-guanine methyltransferase (MGMT), estrogen receptor (ER), retinoic acid receptor beta 2 (RAR beta), and T-type calcium channel (CACNA1G) genes, and methylated in tumor 1 (MINT1), MINT2, MINT25, MINT27, and MINT31 loci by combined bisulfite restriction analysis (COBRA); mutation of K-ras, p53, p16, and p14 genes by sequencing; loss of heterozygosity of chromosome 9p; and microsatellite instability (MSI).

Results: Duodenal carcinomas were methylated more frequently or had increased methylation densities than biliary carcinomas at p14 (P = 0.04), hMLH1 (P = 0.04), MGMT (P = 0.01), MINT1 (P = 0.01), MINT25 (P = 0.01), MINT27 (P = 0.001), RAR beta (P = 0.03), and ER (P = 0.001), and than ampullary carcinomas at RAR beta (P = 0.02) and ER (P = 0.03). In contrast, the methylation profiles of biliary and ampullary carcinomas were not statistically different. Simultaneous methylation of 3 or more CpG islands (CpG island methylator phenotype-high) was more common in duodenal cancers (P = 0.004). MGMT methylation was associated with G-to-A mutation in K-ras (P = 0.006), and hMLH1 methylation was associated with MSI-high (P = 0.01).

Conclusions: Our findings indicate that the methylation profile and genetic alterations of duodenal carcinomas are distinct from biliary and ampullary carcinomas, and that tumor-specific methylation is associated with gene mutation and MSI.

Publication types

  • Comparative Study

MeSH terms

  • Adaptor Proteins, Signal Transducing*
  • Adult
  • Aged
  • Ampulla of Vater / pathology*
  • Biliary Tract Neoplasms / genetics*
  • Biliary Tract Neoplasms / pathology
  • Cadherins*
  • Calcium Channels, T-Type / genetics
  • Carrier Proteins / genetics
  • Chromosomes, Human, Pair 9
  • CpG Islands
  • Cyclin-Dependent Kinase Inhibitor p16 / genetics
  • Cyclooxygenase 2
  • DNA Methylation*
  • Duodenal Neoplasms / genetics*
  • Duodenal Neoplasms / pathology
  • Female
  • Genes, ras / genetics
  • Humans
  • Isoenzymes / genetics
  • Male
  • Membrane Proteins
  • Middle Aged
  • Nerve Tissue Proteins / genetics
  • O(6)-Methylguanine-DNA Methyltransferase / genetics
  • Phenotype
  • Prostaglandin-Endoperoxide Synthases / genetics
  • Protein Serine-Threonine Kinases
  • Proteins / genetics
  • Receptor, Transforming Growth Factor-beta Type II
  • Receptors, Estrogen / genetics
  • Receptors, Retinoic Acid / genetics
  • Receptors, Transforming Growth Factor beta / genetics
  • Tumor Suppressor Protein p53 / genetics

Substances

  • APBA1 protein, human
  • APBA2 protein, human
  • APBA3 protein, human
  • Adaptor Proteins, Signal Transducing
  • Apba1 protein, rat
  • Apba3 protein, rat
  • Cadherins
  • Calcium Channels, T-Type
  • Carrier Proteins
  • Cyclin-Dependent Kinase Inhibitor p16
  • Isoenzymes
  • Membrane Proteins
  • Nerve Tissue Proteins
  • Proteins
  • Receptors, Estrogen
  • Receptors, Retinoic Acid
  • Receptors, Transforming Growth Factor beta
  • Tumor Suppressor Protein p53
  • retinoic acid receptor beta
  • Cyclooxygenase 2
  • PTGS2 protein, human
  • Prostaglandin-Endoperoxide Synthases
  • O(6)-Methylguanine-DNA Methyltransferase
  • Protein Serine-Threonine Kinases
  • Receptor, Transforming Growth Factor-beta Type II